February 6, 2018 / 5:38 PM / 8 months ago

BRIEF-Bavarian Nordic Announces Positive Results Of Pivotal Phase 3 Study Of Imvamune Smallpox Vaccine

Feb 6 (Reuters) - Bavarian Nordic A/S:

* BAVARIAN NORDIC ANNOUNCES POSITIVE RESULTS OF PIVOTAL PHASE 3 STUDY OF IMVAMUNE® SMALLPOX VACCINE

* BLA FILING EXPECTED IN SECOND HALF OF 2018 WITH FAST TRACK DESIGNATION

* SAYS ‍STUDY ACHIEVED BOTH OF ITS PRIMARY ENDPOINTS​

* SECOND POSITIVE PHASE 3 DEMONSTRATING THE SAFETY AND EFFICACY OF IMVAMUNE AND FINAL STUDY REQUIRED FOR LICENSURE, AS AGREED WITH FDA Source text for Eikon: Further company coverage: (Bengaluru Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below